Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Get in-depth healthcare industry analysis with the unparalleled resources at Informa Pharma Intelligence.
Follow the evolution of the Zolgensma story and examine its possible implications for the future of product approval procedures.
Your free Pink Sheet pack includes:
The 2019 Titan of Pharma infographic is a snapshot of the industry’s top leaders and the businesses they oversee, including:
Pharma R&D Annual Review 2019 is based on the stats and data from Pharmaprojects, part of Informa’s Citeline family of intelligence solutions. Authored for the 27th time by Ian Lloyd, Senior Director, Pharmaprojects, this whitepaper contains the whole nine yards:
The ball is in your court: tap into the industry expertise and experience of Ian Lloyd, backed by the rock-solid data from Pharmaprojects download Pharma R&D Annual Review 2019 from Citeline, today.
Listen to our special Spotify playlist while you read. We hope you enjoy this tongue-in-cheek collection of songs, specially curated as the perfect accompaniment to the Pharma R&D Annual Review 2019.
Pink Sheet
A more conservative US Supreme Court may mean a less authoritative FDA, and drug pricing won’t get as much attention in the presidential campaign, which is a good thing.
Topic US Election 2020 FDA
Scrip
Dr Reddy’s combines forces with the Russian Direct Investment Fund for clinical trials and supply of Sputnik V in India, amid what it views as “very important” data points in early studies of the COVID-19 vaccine.
Topic Coronavirus Vaccines
Scrip
Join us for a quick audio roundup of major events in the global biopharma industry over the past week, as reported by Scrip.
Scrip
Olumiant (baricitinib) plus Gilead’s Veklury (remdesivir) provided a statistically significant reduction in time to recovery versus remdesivir alone for hospitalized patients in US NIAID’s ACTT-2 clinical trial.
Scrip
A choice asset in the middle of a pandemic, pharma companies could see the investment bubble burst once normalcy is on the horizon. But interest will continue in innovators, rather than big pharma specifically, predicts an expert panel featuring Biogen's chairman, a former Sanofi CEO and an ex-NIH director
Pink Sheet
Germany is for the first time to adopt national guidelines on prescribing biologics and biosimilars in move towards increasing biosimilar uptake.
Topic EU Biosimilars
Pink Sheet
CBER director said that all the manufacturing data may not be available, but the safety and efficacy data needed for a BLA are expected before an emergency use authorization is granted.
Topic Coronavirus Vaccines
Pink Sheet
Selling government efficiency as a campaign issue has not been an easy task for Democrats. COVID-19 – and especially support for international responses – may present a new opportunity.
Topic US Election 2020 Coronavirus
Pink Sheet
Joe Biden’s presidential campaign now has a plan to address supply chains and encourage US-based manufacturing of prescription drugs. That affirms the unlikely national prominence of the issue – and reduces the chances of meaningful legislation this year.
Pink Sheet
Outgoing Biotechnology Innovation Organization CEO suggests consideration of price inflation caps instead of 'big discounts' in Medicare Part D and says that industry should fund a cap on beneficiary out-of-pocket costs in the program.
Pink Sheet
It is easy to see why Sen. Bernie Sanders would be the least popular pick for biopharma executives among the contenders in the Presidential race. But for industry lobbyists, it might not be the worst outcome – at least in terms of clarifying positions.
Topic US Election 2020
Pink Sheet
Industry balks at President Trump’s latest effort to force biopharma to negotiate a drug pricing solution, but investors may be pushing for concessions that could head off more onerous policies supported by a Biden White House.
Pink Sheet
The US pharmaceutical industry has to be pleased with the tone set by the Democratic National Convention that formally nominated Joe Biden for President. The campaign looks to be about Trump, COVID, and healing racial divisions, not drug prices
Topic US Election 2020
Pink Sheet
US FDA Commissioner Hahn’s credibility is in question following an emergency use authorization for convalescent plasma, leading some former officials to push for new agency leadership. Hahn’s actions, combined with President Trump’s attack on FDA staff as being ‘deep state’ actors, may compromise the public trust in the agency’s work during COVID-19 and beyond, former FDA officials say
Pink Sheet
The latest flurry of Executive Order activity on drug pricing reinforces the message that the President wants to own the headlines for being tough on the drug industry as Election Day looms. Looking for substance beyond that goal is a fool’s errand – but the headlines could still have significant consequences no matter who wins in November.
Topic US Election 2020
Scrip
22 Sep 2020
Pink Sheet
22 Sep 2020
Pink Sheet
22 Sep 2020
HBW Insight
22 Sep 2020
Medtech Insight
22 Sep 2020
Generics Bulletin
22 Sep 2020
HBW Insight
22 Sep 2020
HBW Insight
22 Sep 2020
Generics Bulletin
22 Sep 2020
Pink Sheet
22 Sep 2020
Generics Bulletin
22 Sep 2020
Generics Bulletin
22 Sep 2020
Pink Sheet
22 Sep 2020
Scrip
22 Sep 2020
Scrip
22 Sep 2020
Request a live demo
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
How can we help you?
Our team is always happy to hear from you. Please call us at:
Pharma Report Store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
